Roswell Park-Designed Treatment Regimen Doubles Progression-Free Survival in ...

A phase 1/2 trial for metastatic kidney cancer showed a novel two-agent regimen at Roswell Park doubled progression-free survival compared to single-agent treatment, with median PFS of 23.3 months versus 11.1 months.